Literature DB >> 8756365

Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.

V Villena1, A López-Encuentra, J Echave-Sustaeta, P Martín-Escribano, B Ortuño-de-Solo, J Estenoz-Alfaro.   

Abstract

BACKGROUND: The differential diagnosis of pleural effusion is a frequent clinical problem. Several tumor markers have been evaluated in pleural fluid, but the value of CA 72-4 assay and of combinations of tumor marker assays has not been firmly established. To find a minimally invasive tool for differentiating between pleural effusions of malignant or benign origin, the authors assessed the diagnostic value of CA 72-4, carcinoembryonic antigen (CEA), CA 15-3, and CA 19-9 assays in pleural fluid individually and in combination.
METHODS: The authors prospectively studied 207 patients with pleural effusion (65 malignant, 48 tuberculous, 24 parapneumonic, 26 transudates, 14 miscellaneous, and 30 of unknown nonneoplastic origin). The levels of CA 72-4, CEA, CA 15-3, and CA 19-9 were measured in pleural fluid by radioimmunoassay.
RESULTS: CA 72-4 assay in pleural fluid had an acceptable sensitivity and very good specificity for diagnosing malignant pleural effusion. The combination of CA 72-4 plus CEA plus CA 15-3 yielded the best accuracy, 0.90 (95% confidence interval [CI] 0.85-0.94), with a sensitivity of 0.78 (95% CI, 0.67-0.88), specificity of 0.95 (95% CI, 0.90-0.98), positive predictive value of 0.88 (95% CI, 0.77-0.95), and negative predictive value of 0.91 (range, 0.85-0.94). A good clinical strategy may be to begin with a CEA assay (specificity of I) and then, if it is negative, to add CA 15-3 or even CA 72-4 assays to improve sensitivity. The diagnosis of mesothelioma is more likely with a high CA 15-3 level and normal CEA and CA 19-9 levels.
CONCLUSIONS: Assays of CEA, CA 72-4, and CA 15-3 in pleural fluid, or the combination of CEA with CA 15-3 and CA 72-4, was useful in differentiating between pleural effusion of malignant and benign origin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756365     DOI: 10.1002/(SICI)1097-0142(19960815)78:4<736::AID-CNCR7>3.0.CO;2-C

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients.

Authors:  Sied Mohammad Ali Ghayumi; Samrad Mehrabi; Mehrnossh Doroudchi; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

2.  Diagnostic accuracy of tumour markers in serous effusions: a validation study.

Authors:  Jaume Trapé; Rafael Molina; Francesc Sant; Jesús Montesinos; Anna Arnau; Josefina Franquesa; Rosana Blavia; Esperanza Martín; Emili Marquilles; Damià Perich; Concepción Pérez; Josep Maria Roca; Montserrat Doménech; Joan López; Josep Miquel Badal
Journal:  Tumour Biol       Date:  2012-06-08

Review 3.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Ping Gu; Gang Huang; Yumei Chen; Cuiying Zhu; Jimin Yuan; Shile Sheng
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

4.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09

Review 5.  Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review.

Authors:  S K Mohanty; P Dey
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

6.  Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.

Authors:  G Salama; M Miédougé; P Rouzaud; M A Mauduyt; M C Pujazon; C Vincent; P Carles; G Serre
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.

Authors:  M Miédougé; P Rouzaud; G Salama; M C Pujazon; C Vincent; M A Mauduyt; J Reyre; P Carles; G Serre
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

8.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

9.  Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.

Authors:  Jaume Trapé; Francesc Sant; Josefina Franquesa; Jesús Montesinos; Anna Arnau; Maria Sala; Oscar Bernadich; Esperanza Martín; Damià Perich; Concha Pérez; Joan Lopez; Sandra Ros; Enrique Esteve; Rafael Pérez; Jordi Aligué; Gabriel Gurt; Silvia Catot; Montserrat Domenech; Joan Bosch; Josep Miquel Badal; Mariona Bonet; Rafael Molina; Josep Ordeig
Journal:  Respir Res       Date:  2017-05-25

10.  1H-NMR spectroscopy metabonomics of reactive, ovarian carcinoma and hepatocellular carcinoma ascites.

Authors:  Lucio Zennaro; Lorenzo Nicolè; Paola Vanzani; Filippo Cappello; Ambrogio Fassina
Journal:  Pleura Peritoneum       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.